Lugano, Switzerland, 30 September 2021 – The Molecular Analysis for Precision oncology (MAP) Virtual Congress is designed to answer the critical question about how to integrate the wealth of information coming from the analysis of tumour samples into daily practice.
The programme will provide oncologists with expert guidance to seek and identify actionable mutations in patient’s DNA to provide the best possible personalised treatment.
Major themes
-
Molecular characterisation
-
Clonal evolution
-
Early detection
-
Tumour crosstalk with the microenvironment in metastasis
-
Transcription and translation inhibitors in cancer treatment
-
Spatial techniques for the tumour microenvironment
Keynote lectures
-
‘Understanding immune reactivation by immune checkpoint blockade in human cancer using ex vivo avatars’ by Ton Schumacher, NL – 8 October at 13:45 CEST
-
Gordon Peters lecture: ‘Exploring and therapeutically exploiting the tumour microenvironment’ by Johanna Joyce, CH – 9 October at at 13:45 CEST
Media registration
To apply for media accreditation, please fill out the media registration form.
In addition to having access to live streaming of sessions, live chat and Q&A with invited speakers, e-poster area, virtual exhibition area, and industry satellite symposia, accredited journalists will also have access to the Meeting webcasts.
Further information
MAP Press Office
media@esmo.org
MAP is a joint initiative of Cancer Research UK (CRUK), Unicancer and the European Society for Medical Oncology (ESMO).
-END-
Notes to Editors
Please make sure to use the official name of the meeting in your reports: MAP 2021 Virtual
Official Congress hashtag: #MAP2021
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE.
About Cancer Research UK (CRUK)
We’re the largest charitable funder of cancer research in the world, funding around 50% of all publicly funded cancer research here in the UK. We’re working every day to find new and improved ways to prevent, diagnose and treat cancer, to make it a disease people no longer die from, funding high-calibre, innovative research that we believe has the potential to provide the greatest benefit to the public and cancer patients.
Unicancer is the only French hospital federation dedicated to the fight against cancer, and the only national hospital network exclusively specialised in oncology. It brings together 18 French Comprehensive Cancer Centres (FCCC) and an affiliated member, all non-profit private health care facilities offering a public service and playing a major role in healthcare and research in France.